TP53 and ovarian carcinoma: To explore the mutational characterization of TP53 in patients with breast cancer, we categorized patients into HRD-low (HRD score < 42) and HRD-high (HRD score ≥ 42) groups based on HRD scores, which is the level for HRD in ovarian cancer that has previously been reported [32].